OPKO Health, Inc. (TLV: OPK)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
570.20
-11.90 (-2.04%)
Sep 12, 2024, 5:24 PM IDT
-12.96%
Market Cap 4.03B
Revenue (ttm) 2.70B
Net Income (ttm) -915.28M
Shares Out n/a
EPS (ttm) -1.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 242,412
Open 586.00
Previous Close 582.10
Day's Range 565.00 - 587.90
52-Week Range 315.00 - 645.00
Beta 1.64
Analysts n/a
Price Target n/a
Earnings Date Nov 7, 2024

About OPKO Health

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers,... [Read more]

Sector Healthcare
Founded 2007
Employees 3,930
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol OPK
Full Company Profile

Financial Performance

In 2023, OPKO Health's revenue was $863.50 million, a decrease of -14.01% compared to the previous year's $1.00 billion. Losses were -$188.86 million, -42.49% less than in 2022.

Financial numbers in USD Financial Statements

News

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results

MIAMI, Aug. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2024. Highlights from the second ...

5 weeks ago - GlobeNewsWire

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments

MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPK...

2 months ago - GlobeNewsWire

OPKO Health to Participate in the Jefferies Global Healthcare Conference

MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Global Healthcare Conference, being held June 4-6, 2024 a...

3 months ago - GlobeNewsWire

OPKO Health, Inc. (OPK) Q1 2024 Earnings Call Transcript

Start Time: 16:30 January 1, 0000 5:21 PM ET OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Conference Call May 07, 2024, 16:30 PM ET Company Participants Phil Frost - Chairman and CEO Elias Zerhoun...

4 months ago - Seeking Alpha

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights i...

4 months ago - GlobeNewsWire

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial ...

4 months ago - GlobeNewsWire

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

Transaction to enhance Labcorp's laboratory services network  and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 28, 2024 /PRNewswire/ -- L...

6 months ago - PRNewsWire

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans • Candidate showed similar half-life to standard monoclonal antibo...

6 months ago - GlobeNewsWire

OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript

OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript

7 months ago - Seeking Alpha

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023. Business highlights from...

7 months ago - GlobeNewsWire

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S....

7 months ago - GlobeNewsWire

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes

MIAMI, Jan. 09, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the closing of its previously announced private offering of $230.0 million aggregate principal ...

8 months ago - GlobeNewsWire

OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

Proceeds to be used for privately negotiated repurchases of common stock and outstanding 4.50% Convertible Senior Notes due 2025 Proceeds to be used for privately negotiated repurchases of common stoc...

9 months ago - GlobeNewsWire

OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

Proceeds to be used for privately negotiated repurchases of common stock and outstanding 4.50% Convertible Senior Notes due 2025 Proceeds to be used for privately negotiated repurchases of common stoc...

9 months ago - GlobeNewsWire

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

ELMWOOD PARK, N.J. , Nov. 28, 2023 /PRNewswire/ -- BioReference® Health, LLC (BRH), a leading specialty laboratory in the United States, announced a strategic collaboration with Prognos Health, a pion...

10 months ago - PRNewsWire

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

World-class liquid biopsy testing will be made commercially available to BioReference® customers across the country BOSTON and ELMWOOD PARK, N.J. and ROLLE, Switzerland , Nov. 7, 2023 /PRNewswire/ -- ...

11 months ago - PRNewsWire

OPKO Health, Inc. (OPK) Q3 2023 Earnings Call Transcript

OPKO Health, Inc. (NASDAQ:OPK) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Phillip Frost - Chairman and Chief Executive Of...

11 months ago - Seeking Alpha

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

MIAMI, Nov. 06, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2023. Business highlights f...

11 months ago - GlobeNewsWire

New Clinical Data on OPKO Health's RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) presented late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (AS...

11 months ago - GlobeNewsWire

OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2023 after the close of the U...

11 months ago - GlobeNewsWire

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology ...

11 months ago - GlobeNewsWire

OPKO Health: FDA Approval To Save The Company

OPK and PFE received FDA approval for Ngenla in June. This enables OPK to receive royalties going forward. OPK has continued to lose money due to its lab business. The business had sales fall off foll...

11 months ago - Seeking Alpha

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

Provides Initial $59 Million and up to $168 Million Contingent on Milestones Provides Initial $59 Million and up to $168 Million Contingent on Milestones

1 year ago - GlobeNewsWire

OPKO Health, Inc. (OPK) Q2 2023 Earnings Call Transcript

OPKO Health, Inc. (NASDAQ:OPK) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Phillip Frost - Chairman & Chief Executive Office...

1 year ago - Seeking Alpha

OPKO Health: Improving Profitability Should Drive Shares Forward Post Q2 Earnings

OPKO Health stock has bounced back since February but remains down over 11% since last year. OPK stock's rally in recent months has been supported by strong buying volume and positive earnings revisio...

1 year ago - Seeking Alpha